Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures

  • Yehoshua Z
  • Rosenfeld P
  • Albini T
  • 42


    Mendeley users who have this article in their library.
  • 30


    Citations of this article.


Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

Author-supplied keywords

  • age-related macular degeneration
  • clinical trials
  • drusen
  • geographic atrophy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Zohar Yehoshua

  • Philip J. Rosenfeld

  • Thomas A. Albini

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free